FDA Updates Guidance On ANDAs During COVID
Question And Answer Document Revised To Provide Extra Clarity And Detail
Updated Q&A guidance on developing generics for submission via the abbreviated new drug application pathway during the COVID-19 pandemic has been published by the FDA.
You may also be interested in...
Guidance published by the US FDA in the form of a question-and-answer document addresses questions from ANDA applicants about generic drug development during the COVID-19 pandemic.
Guidance on protecting participants in bioequivalence studies during the COVID-19 pandemic has been published by the FDA.
Celltrion has struck a deal with 180 Life Sciences to supply anti-TNF products to support the company’s work in pursuing new indications for off-patent biologics.